Načítá se...
Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
Bendamustine (Treanda, Ribomustin) was recently approved by the US Food and Drug Administration (FDA) for treatment of patients with rituximab refractory indolent lymphoma and is expected to turn into a frontline therapy option for indolent lymphoma. This compound with amphoteric properties was desi...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Libertas Academica
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3117628/ https://ncbi.nlm.nih.gov/pubmed/21695099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S6085 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|